Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia
Open Access
- 1 August 2012
- journal article
- Published by Taylor & Francis in OncoImmunology
- Vol. 1 (5) , 618-629
Abstract
Although cure rates for acute lymphoblastic leukemia (ALL) have increased, development of resistance to drugs and patient relapse are common. The environment in which the leukemia cells are present...Keywords
This publication has 68 references indexed in Scilit:
- Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemiaLeukemia, 2010
- CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimerNature Immunology, 2009
- The Dectin-2 family of C-type lectins in immunity and homeostasisCytokine, 2009
- The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug Resistance in Chronic Myeloid LeukemiaCancer Cell, 2009
- Pre–B cell receptor–mediated cell cycle arrest in Philadelphia chromosome–positive acute lymphoblastic leukemia requires IKAROS functionJournal of Experimental Medicine, 2009
- CD38/CD31, the CCL3 and CCL4 Chemokines, and CD49d/Vascular Cell Adhesion Molecule-1 Are Interchained by Sequential Events Sustaining Chronic Lymphocytic Leukemia Cell SurvivalCancer Research, 2009
- A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification studyThe Lancet Oncology, 2009
- Hematopoietic prostaglandin D2synthase controls the onset and resolution of acute inflammation through PGD2and 15-deoxyΔ12–14PGJ2Proceedings of the National Academy of Sciences, 2007
- A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenesCancer Cell, 2006
- Inflammation and cancerNature, 2002